 |
市場調查報告書
商品編碼
1741179
範可尼貧血治療市場按治療類型、年齡層、疾病階段和地區分類Fanconi Anemia Drug Market, By Treatment Type, By Age Group, By Disease Stage, By Geography |
||||||
範可尼貧血治療藥物市場預計在 2025 年價值 6.341 億美元，預計到 2032 年將達到 8.982 億美元，2025 年至 2032 年的年複合成長率為 5.1%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 6.341億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期：2025-2032年年複合成長率： | 5.10% | 2032年價值預測 | 8.982億美元 |
範可尼貧血藥物是已研發或正在研發的用於治療範可尼貧血症狀及其潛在基因異常的藥物。範可尼貧血是一種罕見的遺傳性疾病，其特徵是骨髓衰竭、出生缺陷和癌症風險增加。許多器官系統都會受到範可尼貧血的影響。範可尼貧血是由一種缺陷基因引起的，這種基因會損害細胞並阻止其修復受損的DNA。它幾乎影響身體的所有器官。範可尼貧血也被稱為遺傳性再生障礙性貧血。
市場動態：
預計在預測期內，科學研究的持續進步和對分子機制的了解將推動範可尼貧血藥物市場的成長。在預測期內，龐大的未滿足醫療需求也將繼續推動範可尼貧血藥物市場的成長。這項因素促使研發人員努力尋找控制和治療 FA 的有效治療方法。在預測期內，疾病修正治療的發展可能為全球範可尼貧血藥物市場帶來新的機會。有機會研發出能夠解決與 FA 相關的基因改變和分子機制的疾病緩解疾病藥物。例如，2022 年 5 月 17 日，生物技術公司 Jasper Therapeutics, Inc. 宣佈在史丹佛大學醫學院確定和治療醫學中心 (CDCM) 贊助的一項研究中對第一位患者進行給藥，該研究將 JPS191 作為治療範可尼貧血的調理劑。根據該協議，史丹佛大學醫學院正在對患有範可尼貧血和骨髓衰竭、需要接受非兄弟姐妹供體異基因移植的患者進行 JSP191 的 1/2 期臨床試驗 (NCT04784052)。
本研究的主要特點
- 本報告對全球範可尼貧血治療市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
- 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
- 全球範可尼貧血治療藥物市場的主要企業根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數進行分析。
- 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
- 全球範可尼貧血治療藥物市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過用於分析全球範可尼貧血藥物市場的各種策略矩陣來促進決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 科學研究和分子機制理解的不斷進步
- 未滿足的醫療需求
- 限制因素
- 缺乏公認的治療方法
- 機會
- 疾病修正治療的開發
- 影響分析
- 主要亮點
- 監管情景
- 產品發布/核准
- PEST分析
- 波特分析
- 併購場景
4. 全球範可尼貧血治療市場-冠狀病毒（COVID-19）大流行的影響
- COVID-19流行病學
- 供需側分析
- 經濟影響
5. 2020 年至 2032 年全球範可尼貧血治療市場（依治療類型）
- 造血生長因子
- 基因治療
- 幹細胞移植
- 其他治療方法
6. 2020 年至 2032 年按年齡層分類的全球範可尼貧血治療市場
- 兒科患者
- 成年患者
7. 2020 年至 2032 年全球範可尼貧血治療市場（依疾病階段分類）
- 最初的
- 晚期
8. 2020 年至 2032 年全球範可尼貧血治療市場（按地區）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東地區
- 非洲
- 南非
- 北非
- 中部非洲
第9章 競爭態勢
- Foresee Pharmaceuticals Co., Ltd.
- Rocket Pharmaceuticals Inc.
- Amgen
- Novartis AG
- Gilead Sciences, Inc.（Kite Pharma, Inc.）
- Celgene Corporation（Juno Therapeutics）
- Spark Therapeutics
- UniQure NV
- Bluebird Bio, Inc.
- PTC Therapeutics
- Orchard Therapeutics Limited
- GlaxoSmithKline Plc.
- Aurora Biopharma, Inc.
- Pfizer, Inc.
- Autolus Therapeutics
第 10 章 章節
- 調查方法
- 關於出版商
Fanconi Anemia Drug Market is estimated to be valued at USD 634.1 Mn in 2025 and is expected to reach USD 898.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 634.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.10% | 2032 Value Projection: | USD 898.2 Mn |
The fanconi anemia drugs are pharmaceutical therapies and treatments that have been created or are currently being researched with the goal of treating the symptoms and underlying genetic abnormalities of fanconi anemia, a rare genetic disorder that is marked by bone marrow failure, congenital defects, and an increased risk of developing cancer. Numerous organ systems are impacted by fanconi anemia. Fanconi anemia results from a defective gene that harms cells, and prevents them from mending damaged DNA. It has an impact on practically all body organs. It is also known as aplastic anemia that is hereditary.
Market Dynamics:
Continuous advancements in scientific research and knowledge about molecular mechanisms are expected to drive the global fanconi anemia drug market growth over the forecast period. Substantial unmet medical need will also continue to fuel growth of the global fanconi anemia drug market over the forecast period. This element motivates efforts in research and development to find efficient therapeutics for the control and treatment of FA. Development of disease-modifying therapies will create new opportunities for the global fanconi anemia drug market over the forecast period. There are opportunities for the creation of disease-modifying medications that can deal with the genetic alterations and molecular mechanisms connected to FA. For instance, on May 17, 2022, Jasper Therapeutics, Inc., a biotechnology company, announced the dosing of the first patient in its sponsored research of the Center for Definitive and Curative Medicine (CDCM) at the Stanford University School of Medicine for the study of JPS191 as a conditioning agent in the treatment of Fanconi Anemia. In accordance with the sponsored research agreement, Stanford Medicine is conducting a Phase 1/2 clinical trial (NCT04784052) utilizing JSP191 to treat Fanconi Anemia patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.
Key features of the study:
- This report provides in-depth analysis of the global fanconi anemia drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global fanconi anemia drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Foresee Pharmaceuticals Co., Ltd., Rocket Pharmaceuticals Inc., Amgen, Novartis AG, Gilead Sciences, Inc. (Kite Pharma, Inc.), Celgene Corporation (Juno Therapeutics), Spark Therapeutics, UniQure N.V, Bluebird Bio, Inc., PTC Therapeutics, Orchard Therapeutics Limited, GlaxoSmithKline Plc., Aurora Biopharma, Inc., Pfizer, Inc. and Autolus Therapeutics
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global fanconi anemia drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fanconi anemia drug market
Detailed Segmentation:
- By Treatment Type:
- Hematopoietic Growth Factors
- Gene Therapy
- Stem Cell Transplantation
- Other Therapies
- By Age Group:
- Pediatric Patients
- Adult Patients
- By Disease Stage:
- Early-stage Disease
- Advanced-stage Disease
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Foresee Pharmaceuticals Co., Ltd.
- Rocket Pharmaceuticals Inc.
- Amgen
- Novartis AG
- Gilead Sciences, Inc. (Kite Pharma, Inc.)
- Celgene Corporation (Juno Therapeutics)
- Spark Therapeutics
- UniQure N.V
- Bluebird Bio, Inc.
- PTC Therapeutics
- Orchard Therapeutics Limited
- GlaxoSmithKline Plc
- Aurora Biopharma, Inc.
- Pfizer, Inc.
- Autolus Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Fanconi Anemia Drug, By Treatment Type
- Market Fanconi Anemia Drug, By Age Group
- Market Fanconi Anemia Drug, By Disease Stage
- Market Fanconi Anemia Drug, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Continuous advancements in scientific research and understanding of the molecular mechanisms
- Substantial unmet medical need
- Restraints
- Lack of recognized therapies
- Opportunities
- Development of Disease-Modifying Therapies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Fanconi Anemia Drug Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Fanconi Anemia Drug Market, By Treatment Type, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Hematopoietic Growth Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Stem Cell Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Other Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
6. Global Fanconi Anemia Drug Market, By Age Group, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
7. Global Fanconi Anemia Drug Market, By Disease Stage, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Early-stage Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Advanced-stage Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
8. Global Fanconi Anemia Drug Market, By Region, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Foresee Pharmaceuticals Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rocket Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gilead Sciences, Inc. (Kite Pharma, Inc.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Celgene Corporation (Juno Therapeutics)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Spark Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- UniQure N.V
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bluebird Bio, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PTC Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Orchard Therapeutics Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aurora Biopharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Autolus Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
